Cardiol Therapeutics Inc. (CRDL)

Market Cap	147.10M +64.9%
Revenue (ttm)	n/a
Net Income	-24.67M
EPS	-0.28
Shares Out	111.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	578,661
Open	1.330
Previous Close	1.300
Day's Range	1.280 - 1.335
52-Week Range	0.880 - 1.710
Beta	0.43
Analysts	Strong Buy
Price Target	8.50 (+543.94%)
Earnings Date	May 14, 2026

About CRDL

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol fo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2017
• Employees: 18
• Stock Exchange: NASDAQ
• Ticker Symbol: CRDL
• Website: https://www.cardiolrx.com

Financial Performance

Financial numbers in CAD

Analyst Summary

According to 2 analysts, the average rating for CRDL stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 543.94% from the latest price.

Price Target

$8.5

(543.94% upside)

Analyst Consensus: Strong Buy